A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple Myeloma
NCT ID: NCT04036461
Last Updated: 2024-08-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE1
47 participants
INTERVENTIONAL
2019-08-26
2024-08-19
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma
NCT03486067
Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT04975399
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT04634552
BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma
NCT00346255
A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment
NCT04035226
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm 1 (CC-99712 monotherapy)
CC-99712 will be administered via intravenous (IV) infusion.
CC-99712
CC-99712
Arm 2 (CC-99712 and BMS-986405 combination)
CC-99712 will be administered via IV infusion. BMS-986405 will be administered orally.
CC-99712
CC-99712
BMS-986405
BMS-986405
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CC-99712
CC-99712
BMS-986405
BMS-986405
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participant has a history of multiple myeloma (MM) with relapsed and/or refractory disease
* Participant must have measurable disease.
* Participant has an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1.
Exclusion Criteria
* Participant had a prior autologous stem cell transplant ≤ 3 months prior to starting CC-99712.
* Participant had a prior allogeneic stem cell transplant with either standard or reduced intensity conditioning ≤ 6 months prior to starting CC-99712 or is on systemic immunosuppression for graft-versus host disease.
* Subject is a pregnant or lactating female.
* Subject has known human immunodeficiency virus (HIV) infection.
* Subject has active hepatitis B or C (HBV/HCV) infection.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Celgene
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Bristol-Myers Squibb
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Local Institution - 107
La Jolla, California, United States
Local Institution - 105
Sarasota, Florida, United States
Local Institution - 103
Buffalo, New York, United States
Local Institution - 106
New York, New York, United States
Local Institution - 101
Portland, Oregon, United States
Local Institution - 104
Dallas, Texas, United States
Local Institution - 102
Seattle, Washington, United States
Local Institution - 202
Toronto, Ontario, Canada
Local Institution - 201
Montreal, Quebec, Canada
Institut Paoli Calmettes
Marseille, , France
CHU Montpellier - Hôpital Saint Eloi
Montpellier, , France
Hopital Saint Antoine
Paris, , France
Local Institution - 305
Pierre-Bénite, , France
Local Institution - 501
Bologna, , Italy
Local Institution - 405
Barcelona, , Spain
Local Institution - 401
Madrid, , Spain
Local Institution - 0505
Málaga, , Spain
Local Institution - 402
Salamanca, , Spain
Local Institution - 404
Sevillla, , Spain
Local Institution - 403
Valencia, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
BMS Clinical Trial Information
BMS Clinical Trial Patient Recruiting
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
U1111-1231-9404
Identifier Type: OTHER
Identifier Source: secondary_id
2020-004514-35
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
CC-99712-MM-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.